Combinatorial inhibition of MEK/ERK and γ-secretase increases efficacy in melanoma, papillary thyroid cancer, and CRC (Krepler et al., 2016, Yamashita et al., 2013, Schmidt et al., 2018). Here, EPHB2 is linked to melanoma.